39 results about "Atony" patented technology

The invention relates to the technical field of Chinese medicaments, in particular to a medicament for treating cervical spondylosis. The medicament comprises the following raw materials in parts by weight: 80 to 120 parts of cassia twig, 100 to 180 parts of white peony root, 200 to 340 parts of kudzuvine root, 100 to 160 parts of Szechuan lovage rhizome, 80 to 120 parts of zedoary, 100 to 160 parts of rhizoma corydalis, 170 to 230 parts of fried jujube kernel, 170 to 220 parts of astragalus root, 90 to 150 parts of Chinese angelica, 170 to 210 parts of tuckahoe, 90 to 110 parts of bupleurum, and 80 to 130 parts of Baikal skullcap root. Based on the therapeutic principles of tonifying qi, activating blood, diffusing impediment and dredging collaterals, the medicament is suitable for treating the cervical spondylosis (nerve root type or vertebra artery type) caused by qi deficiency and blood stasis, is used for treating the symptoms such as arm numbness or disability, pains of neck, shoulders and arms, giddiness and headache, and is quick in response, good in curative effect and convenient to take.

Embodiments of the invention include methods of treating, preventing, and / or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness, cachexia, and a combination thereof in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and / or reduction in the risk of muscle wasting. In at least particular cases, the small molecules are inhibitors of STAT3.

Embodiments of the invention include methods of treating, preventing, and / or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness, cachexia, and a combination thereof in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and / or reduction in the risk of muscle wasting. In at least particular cases, the small molecules are inhibitors of STAT3.

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The invention relates to a Chinese medicine preparation used for the treatment of the forestomach atony of milk cows, and a preparation method thereof. The Chinese medicine preparation is characterized in that the preparation comprises the following drugs according to parts by weight: 60 to150 portions of radix codonopsis pilosulae, 40 to 80 portions of tuckahoe, 40 to 80 portions of liquorice (roasted), 50 to 100 portions of radix puerariae, 20 to 40 portions of radix aucklandiae and 20 to 40 portions of rhizoma zingiberis. The preparation method is that: after being comminuted into ultra-micro powder, the drugs are evenly mixed according to proportion, or extracted by heating to make oral liquid, that is, prepared drug in pieces are weighted proportionally, then added with water 5 to 10 times more than the powder, dipped for 20 to 40 minutes, decocted for 50 to 80 minutes and filtered to be condensed to the drug content of 0.5g to 1g per milliliter, thus the Chinese medicine preparation is prepared. The Chinese medicine preparation of the invention has no residues and no toxic and side effects. The Chinese medicinal materials of the invention are comminuted in a super-micro way to be led to pass through a sieve of 100 meshes to 300 meshes, and plant cell walls are damaged to the maximum extent, thus overcoming the defects of the high content of crude fiber and the difficult stripping of active ingredients of Chinese medicine pulvis; the oral liquid is prepared by heating and extracting so as to ensure more convenient use and faster absorption and utilization, thereby being capable of effectively treating the forestomach atony of the milk cows.

This invention relates to selective m1 muscarinic agonist, their use or a formulation thereof in the treatment of glaucoma and / or other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans. In addition, the present invention relates to the use of the compounds in the treatment of dementia such as Alzheimer's disease and vascular dementia, depression, attention deficit disorder, sleep disorder, schizophrenia, pain, ischemia, atrophic gastritis, and atony of gastrointestinal tract.

The invention discloses a medicament for treating atony of forestomach in sheep, prepared from the following raw materials in weight: 20g of roasted malt, 20g of medicated leaven, 15g of costus root, 20g of officinal magnolia bark, 20g of betel palm, 20g of tuckahoe, 10g of corydalis root, 20g of angelica, 20g of bighead atractylodes rhizome, 20g of Chinese atractylodes, 15g of dried orange peel, 20g of mirabilite, 10g of licorice and 30g of rhubarb. The medicament disclosed by the invention has easy availability of raw materials, is simple to prepare, and has the efficacies of strengthening the spleen, regulating the flow of qi, promoting digestion, resolving food stagnancy and enhancing gastrointestinal peristalsis.

A method for preparation pharmaceutical compounds in large quantities consists of copper (I) halide, preferably the chloride complex of nicotinic acid characterized by elemental analysis, spectroscopy and crystallographic methods, used for treatment of muscular dystrophy, myopathy, myasthenia gravis, parkinsonism, Chronic Fatigue Syndrome, Male Infertility and post stroke muscle weakness.Chlorobis (nicotinic acid) copper (I) monohydrate complex, its composition [CuCl(nicotinic acid)2]. H2O, has been prepared and its physical and chemical properties as well as its crystal structure have been investigated for the first time.

Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral / anal sphincter muscle.

The present invention relates to ALK5 inhibitors and their uses as skeletal muscle hypertrophy inducers as well as to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting in loss of skeletal muscle tissue and / or muscle weakness. It further relates to the non-therapeutic use of such compounds to increase musclemass, muscle strength and / or muscle performance in a subject.

The present disclosure relates generally to methods of restoring neuromuscular transmission by locally administering an effective dose of a composition comprising an anticholinesterase to a non-responsive muscle. The disclosure also relates to methods of reversing a neurotoxin-induced muscle paralysis or muscle weakness, the method comprising locally administering a composition comprising an anticholinesterase to the patient.

The invention discloses a medicine for preventing and curing forestomach atony of ruminants, being prepared with the medicines according to a certain proportion: (fried) nuxvomica, areca seed, pharbitidis seed, euphorbia root, medicated leaven, hawthorn fruit, malt, Chinese rhubarb, mirabilite, stertite, antimony potassium tartrate and sodium bicarbonate, which (except mirabilite and stertite) are sun-dried, purified, crushed, and then grinded with two western medicines, sieved through an 80 to 100-mesh screen and finally mixed evenly. In clinical practice, the medicines are socked in boiled water for 30-60 minutes, of which the effective ingredients are dissolved and precipitated for improving the absorption rate of the medicine which is one-time drenched when cool. The medicine of the invention has quicker efficacy and smaller dosage compared with the single use of traditional Chinese medicine, longer maintenance time of drug effect and more difficult recurring compared with the single use of western medicine, and is difficult to develop the immunity to drugs, effectively releases or eliminates in vivo metabolic acidosis, greatly reduces death rate without a untoward reaction and with higher clinic cure rate. With simple preparation method and convenient use, the invention can be widely used in the breeding industry.

The present invention relates to a composition and a kit for diagnosis of muscle weakness-related disease, which comprises agents for measuring the expression levels of gelsolin and tetranectin, and to a method of diagnosing muscle weakness-related disease by using the same. The composition, kit and method for diagnosis of muscle weakness-related disease according to the present invention make it possible to diagnose muscle weakness-related disease in an easy and rapid manner by molecular diagnosis, thereby systemically managing the muscle weakness-related disease while increasing therapeutic efficacy against the muscle weakness-related disease.

A traditional Chinese medicine preparation is used as a new medicine for treating osteoarthritis. The clinical symptoms of osteoarthritis are: degeneration and destruction of articular cartilage, subchondral bone sclerosis or cystic degeneration, bone hyperplasia at the joint edge, synovial hyperplasia, Joint capsule contracture, ligament laxity or contracture, muscle atrophy and weakness, etc.; the traditional Chinese medicine preparation is made of the following raw materials in parts by weight: 700-1100 parts of red fish eye, 700-1100 parts of nine-layer wind, 450-800 parts of Ivy clover , 450-800 parts of Shanfeng, 160-320 parts of Liangmianzhen, 25-40 parts of Panax notoginseng stems and leaves, among which Shanfeng can also be replaced by an equal amount of Dafeng AI. The present invention uses the medicine originally used for treating rheumatoid arthritis, frozen shoulder and rheumatoid arthritis to treat osteoarthritis, and has remarkable curative effect in treating osteoarthritis, expands the indications of the original medicine, and provides a clinical A new drug for the prevention and treatment of osteoarthritis.

The invention relates to the technical field of Chinese medicaments, in particular to a medicament for treating cervical spondylosis. The medicament comprises the following raw materials in parts by weight: 80 to 120 parts of cassia twig, 100 to 180 parts of white peony root, 200 to 340 parts of kudzuvine root, 100 to 160 parts of Szechuan lovage rhizome, 80 to 120 parts of zedoary, 100 to 160 parts of rhizoma corydalis, 170 to 230 parts of fried jujube kernel, 170 to 220 parts of astragalus root, 90 to 150 parts of Chinese angelica, 170 to 210 parts of tuckahoe, 90 to 110 parts of bupleurum, and 80 to 130 parts of Baikal skullcap root. Based on the therapeutic principles of tonifying qi, activating blood, diffusing impediment and dredging collaterals, the medicament is suitable for treating the cervical spondylosis (nerve root type or vertebra artery type) caused by qi deficiency and blood stasis, is used for treating the symptoms such as arm numbness or disability, pains of neck, shoulders and arms, giddiness and headache, and is quick in response, good in curative effect and convenient to take.

The present invention relates to sobrerol or a pharmaceutically acceptable salt thereof, which can promote differentiation of myoblasts to form myotubes, thereby preventing muscle weakness and effectively improving muscle functions. Therefore, the pharmaceutical composition containing the same can be effectively used for preventing or treating muscle weakness related diseases.